BofA analyst Travis Steed initiated coverage of Carlsmed (CARL) with a Buy rating and $16 price target The firm says the company’s Aprevo platform is ushering in a new standard of care in spine fusion surgery with custom 3D printed interbody implants. BofA’s views its forecast of Carlsmed adding 20-25 new surgeons each quarter through 2027 as conservative.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARL: